Sumitomo Life Insurance Co. Acquires 1,841 Shares of Thermo Fisher Scientific Inc. $TMO

Sumitomo Life Insurance Co. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,771 shares of the medical research company’s stock after purchasing an additional 1,841 shares during the period. Thermo Fisher Scientific comprises 0.7% of Sumitomo Life Insurance Co.’s portfolio, making the stock its 27th biggest holding. Sumitomo Life Insurance Co.’s holdings in Thermo Fisher Scientific were worth $10,449,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC raised its stake in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter valued at approximately $30,000. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter valued at approximately $31,000. DiNuzzo Private Wealth Inc. raised its stake in shares of Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC raised its stake in shares of Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 45 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on TMO. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the company an “overweight” rating in a report on Tuesday. TD Cowen raised their price target on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Finally, UBS Group raised their price target on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. Nineteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total transaction of $229,660.00. Following the transaction, the executive vice president directly owned 21,152 shares of the company’s stock, valued at $12,144,420.80. This trade represents a 1.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 54,420 shares of company stock valued at $28,134,684. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO opened at $568.25 on Friday. The company has a fifty day moving average price of $510.86 and a two-hundred day moving average price of $457.75. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The firm has a market capitalization of $214.58 billion, a PE ratio of 32.83, a P/E/G ratio of 3.27 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the previous year, the business earned $5.28 EPS. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.